Alder Biopharmaceuticals Inc  

(Public, NASDAQ:ALDR)   Watch this stock  
Find more results for John C. Rutherford
-0.30 (-0.98%)
Real-time:   10:14AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 30.07 - 30.53
52 week 15.82 - 47.90
Open 30.50
Vol / Avg. 51,163.00/715,245.00
Mkt cap 1.52B
P/E     -
Div/yield     -
EPS -2.77
Shares 50.18M
Beta     -
Inst. own 103%
Jul 26, 2016
Q2 2016 Alder Biopharmaceuticals Inc Earnings Call
Jul 26, 2016
Q2 2016 Alder Biopharmaceuticals Inc Earnings Release
Jun 7, 2016
Alder Biopharmaceuticals Inc at Jefferies Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -34394.69% -
Operating margin -34733.63% -
EBITD margin - -
Return on average assets -36.82% -36.81%
Return on average equity -38.22% -38.27%
Employees 113 -
CDP Score - -


11804 N Creek Pkwy S
BOTHELL, WA 98011-8801
United States - Map
+1-425-2052900 (Phone)
+1-425-2052901 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Alder Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and focuses to commercialize therapeutic antibodies with the potential to transform current treatment paradigms. The Company has developed an antibody platform designed to select antibodies that have the potential to maximize efficacy, as well as speed of onset and durability of therapeutic response. The Company's pipeline includes ALD403, Clazakizumab and ALD1613. ALD403 is the Company's monoclonal antibody targeted to calcitonin gene-related peptide (CGRP) for migraine prevention. Clazakizumab is a monoclonal antibody that inhibits the pro-inflammatory cytokine interleukin-6 (IL-6), and is in development for both rheumatoid arthritis (RA) and psoriatic arthritis (PsA). ALD1613 is a monoclonal antibody that inhibits Adrenocorticotropic Hormone (ACTH), and is being developed for the treatment of Cushing's disease. It is also developing ALD403 program for migraine prevention.

Officers and directors

Stephen M. Dow Independent Chairman of the Board
Age: 60
Bio & Compensation  - Reuters
Randall C. Schatzman Ph.D. President, Chief Executive Officer, Director
Age: 60
Bio & Compensation  - Reuters
Larry K. Benedict Senior Vice President - Finance
Age: 54
Bio & Compensation  - Reuters
Randal A. Hassler Senior Vice President, Pharmaceutical Operations
Age: 57
Bio & Compensation  - Reuters
Jeffrey T.L. Smith M.D. Senior Vice President, Translational Medicine
Age: 55
Bio & Compensation  - Reuters
John A. Latham Ph.D. Chief Scientific Officer
Age: 55
Bio & Compensation  - Reuters
Mark J. Litton Ph.D. Chief Business Officer, Treasurer and Secretary
Age: 47
Bio & Compensation  - Reuters
Paul Rutherford Carter Director
Age: 55
Bio & Compensation  - Reuters
Paul B. Cleveland Director
Age: 59
Bio & Compensation  - Reuters
Gary J. Bridger Ph.D. Independent Director
Age: 52
Bio & Compensation  - Reuters